Nemaura Medical Inc. Reveals Attendance at This Year's H.C. Wainwright Global Investment Conference

• The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
• Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
• The company recently revealed its participation at the annual H.C. Wainwright Global Investment Conference, held between September 13-15, 2021
• Through its sugarBEAT flagship product, Nemaura has sought to capitalize on the expanding Type 2 Diabetes market, expected to reach an annual value of $59 billion by 2025

Nemaura Medical NMRD is a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs; the company’s flagship product, the sugarBEAT(R), is a wearable, non-invasive and flexible Continuous Glucose Monitor designed to help people with diabetes and prediabetes manage their glucose levels.

Nemaura Medical’s management recently revealed their attendance at the 23rd Annual H.C. Wainwright Global Investment Conference, held in an entirely digital forum between September 13-15, 2021 (https://ibn.fm/1OiBy). Initially founded in 1868, H.C. Wainwright is a…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Image by 정훈 김 from Pixabay

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.